跳至主要内容
临床试验/EUCTR2007-001174-81-SE
EUCTR2007-001174-81-SE进行中(未招募)1 期

RANDOMIZED MULTICENTER PHASE III STUDY IN PATIENTS WITH LOCALLY ADVANCED ADENOCARCINOMA OF THE PANCREAS: GEMCITABINE WITH OR WITHOUT CHEMORADIOTHERAPY AND WITH OR WITHOUT ERLOTINIB - GERCOR - LAP 07

GOF pancreatic cancer collaborative group0 个研究点目标入组 442 人开始时间: 2009年7月8日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
442

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Histologically approven adenocarcinoma of the pancreas.
  • Locally advanced non-resectable tumour.
  • Measurable or evaluable disease (RECIST).
  • No prior radiotherapy nor chemotherapy.
  • Performance status 0 - 2.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years)
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years)
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Resectable or metastatic cancer.
  • Periampullar cancer.
  • Other cancer within five years.

研究者

发起方
GOF pancreatic cancer collaborative group

相似试验

进行中(未招募)
不适用
RANDOMIZED MULTICENTER PHASE III STUDY IN PATIENTS WITH LOCALLY ADVANCED ADENOCARCINOMA OF THE PANCREAS: GEMCITABINE WITH OR WITHOUT CHEMORADIOTHERAPY AND WITH OR WITHOUT ERLOTINIB - LAP 07Patients with de novo locally advanced, histologically proven adenocarcinoma of the pancreas without distant metastases (stage III according to the UICC classification) and not considered for curative resection after pluridisciplinary discussion.MedDRA version: 9.1Level: LLTClassification code 10052747Term: Adenocarcinoma pancreas
EUCTR2007-001174-81-FRGERCOR820
进行中(未招募)
1 期
RANDOMIZED MULTICENTER PHASE III STUDY IN PATIENTS WITH LOCALLY ADVANCED ADENOCARCINOMA OF THE PANCREAS: GEMCITABINE WITH OR WITHOUT CHEMORADIOTHERAPY AND WITH OR WITHOUT ERLOTINIB - LAP 07
EUCTR2007-001174-81-BEB Erasme Hospital902
已完成
不适用
Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer-C50 Malignant neoplasm of breastMalignant neoplasm of breastC50
PER-045-04GLAXOSMITHKLINE PERU S.A.,40
已完成
不适用
Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone
PER-055-04BRISTOL MYERS SQUIBB COMPANY,
进行中(未招募)
1 期
RANDOMIZED PHASE III MULTICENTRE STUDY INVESTIGATING THE ROLE OF LETROZOLE IN HEAVILY PRETREATED RECURRENT OVARIAN CANCERADVANCED OVARIAN CANCERMedDRA version: 21.1Level: PTClassification code 10054913Term: Serous cystadenocarcinoma ovarySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2019-001623-12-ITFONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE236